Combination regimens including tusamitamab ravtansine have demonstrated activity in a phase 2 study of patients with CEACAM5+ non-small cell lung cancer.
Upfront osimertinib can reduce the risk of brain progression, when compared with gefitinib followed by osimertinib, in advanced EGFR-mutant NSCLC, a study suggests.
Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy, a study suggests.